Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4′-methyl-α-pyrrolidinobutyrophenone

Drug Metabolism and Disposition

Volumn 36, Issue 1, 2008, Pages 163-168

  Peters, Frank T ^a   Meyer, Markus R ^a   Theobald, Denis S ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4' METHYL ALPHA PYRROLIDINOBUTYROPHENONE; ALPHA NAPHTHOFLAVONE; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIGNER DRUG; DRUG METABOLITE; FLUCONAZOLE; QUINIDINE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; BACULOVIRIDAE; BUTYROPHENONES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DESIGNER DRUGS; ENZYME INHIBITORS; GENETIC VECTORS; HUMANS; HYDROXYLATION; INSECTS; ISOENZYMES; MASS SPECTROMETRY; MICROSOMES, LIVER; PYRROLIDINES; TRANSFECTION;

HEXAPODA;

EID: 37549045269     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017293     Document Type: Article

References (40)

1. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192-209.
2. Bourrie M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
3. Cawley GF, Zhang S, Kelley RW, and Backes WL (2001) Evidence supporting the interaction of CYP2B4 and CYP1A2 in microsomal preparations. Drug Metab Dispos 29:1529-1534.
4. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
5. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research, in Advances in Drug Research (Testa B and Meyer UA eds) pp 179-235, Academic Press, London.
6. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacol Ther 84:121-131.
7. Crespi CL and Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43:171-188.
8. Crewe HK, Lennard MS, Tucker GT, Woods FR, and Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265.
9. Deniker P, Loo H, Cuche H, and Roux JM (1975) [Abuse of pyrovalerone by drug addicts]. Ann Med Psychol (Paris) 2:745-748.
10. Fauquet JP, Morel E, Demarty C, and Rapin JR (1976) [Role of central catecholamines in the psychostimulant activity of pyrovalerone]. Arch Int Pharmacodyn Ther 224:325-337.
11. Goldberg J, Gardos G, and Cole JO (1973) A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 8:60-69.
12. Guengerich FP (2005) Human cytochrome P450 enzymes, in Cytochrome P450 - Structure, Mechanism, and Biochemistry (Ortiz-de-Montellano PR ed) pp 377-530, Kluwer Academic/Plenum Publishers, New York.
13. Hazai E and Kupfer D (2005) Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes. Drug Metab Dispos 33:157-164.
14. Heimann H and Lukacs G (1965) [Experimental psychological differentiation of the effect of 2 psychostimulants (F-1983 and amphetamine) in humans.] Psychopharmacologia 8:79-90.
15. Heinmann H and Vetter K (1965) [Clinical studies of a new psychostimulant (F-1983).] Schweiz Med Wochenschr 95:306-309.
16. Holliday AR, Morris RB, and Sharpley RP (1964) Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6:192-200.
17. Lho DS, Lee J, Kim S, Park J, and Shin HS (1996) Identification of a pyrovalerone metabolite in the rat by gas chromatography-mass spectrometry and determination of pyrovalerone by gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Appl 687:253-259.
18. Maurer HH, Kratzsch C, Weber AA, Peters FT, and Kraemer T (2002) Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxy carbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry. J Mass Spectrom 37:687-692.
19. Meltzer PC, Butler D, Deschamps JR, and Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420-1432.
20. Michaelis W, Russel JH, and Schindler O (1970) The metabolism of pyrovalerone hydrochloride. J Med Chem 13:497-503.
21. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
22. Peters FT, Dragan CA, Wilde DR, Meyer MR, Bureik M, and Maurer HH (2007) Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4′-hydroxymethyl-alpha-pyrrolidinobutyrophenone. Biochem Pharmacol 74:511-520.
23. Peters FT, Meyer MR, Fritschi G, and Maurer HH (2005) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 824:81-91.
24. Roesner P, Junge T, Fritschi G, Klein B, Thielert K, and Kozlowski M (1999) Neue synthetische Drogen: Piperazin-, Procyclidin- und alpha-Aminopropiophenonderivate. Toxichem Krimtech 66:81-90.
25. Servin A, Fauquet JP, Jacquot C, and Rapin JR (1978) Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem Pharmacol 27:1693-1694.
26. Shin HS, Shin YS, Lee S, and Park BB (1996) Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 20:568-572.
27. Smith DA, Abel SM, Hyland R, and Jones BC (1998) Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 28:1095-1128.
28. Soderholm S, Viukari NM, and Rimon R (1976) [The psychotropic effect of the Pyrovalerone (F-1983), placebo, the milieu therapy and mental condition of the patients in forensic psychiatry]. Nervenarzt 47:88-93.
29. Springer D, Fritschi G, and Maurer HH (2003a) Metabolism and toxicological detection of the new designer drug 3′,4′- methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793:377-388.
30. Springer D, Fritschi G, and Maurer HH (2003b) Metabolism and toxicological detection of the new designer drug 4′-methoxy-α- pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793:331-342.
31. Springer D, Fritschi G, and Maurer HH (2003c) Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 796:253-266.
32. Springer D, Paul LD, Staack RF, Kraemer T, and Maurer HH (2003d) Identification of the cytochrome P450 enzymes involved in the metabolism of 4′-methyl-(alpha)-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab Dispos 31:979-982.
33. Springer D, Paul LD, Staack RF, Kraemer T and Maurer HH (2003e) Involvement of human hepatic cytochrome P450 isoenzymes in the metabolism of the new pyrrolidinophenone designer drugs MPPP, MOPPP, MDPPP and MPHP, in Proceedings of the XIIIth GTFCh Symposium in Mosbach (Pragst F and Aderjan R eds), pp 204-211, Helm-Verlag, Heppenheim (Germany).
34. Springer D, Peters FT, Fritschi G, and Maurer HH (2003f) New designer drug 4′-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 789:79-91.
35. Springer D, Peters FT, Fritschi G, and Maurer HH (2002) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 773:25-33.
36. Stille G, Ackermann H, Eichenberger E, and Lauener H (1963) [Comparative pharmacological study of a new central stimulant, 1-p-tolyl-1-oxo-2-pyrrolidino- n-pentane HCl]. Arzneim-Forsch 13:871-877.
37. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000a) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
38. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2000b) Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance. Clin Pharmacokinet 38:111-180.
39. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
40. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, and Trager WF (1996) Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 24:610-614.